论文部分内容阅读
目的评价肺腺癌患者的CT及临床特征与表皮生长因子受体(EGFR)19号外显子突变之间的相关性。方法纳入的581例患者均行CT扫描和EGFR基因检测,所需要定性评估的CT及临床特征共有25个。应用单因素对比分析及Logistic回归模型对EGFR野生型和19号外显子突变型的特征相关性进行分析。P值<0.05为差异有统计学意义。结果 581例患者中,突变型共132例(22.7%),野生型为449例(77.3%)。EFGR19号外显子突变型与较小的肿瘤最大径(OR=0.982)、女性(OR=0.380)、胸膜牵拉(OR=2.093)以及无纤维化(OR=0.288)4个特征有关。结论肺腺癌的某些CT及临床特征与EGFR19号外显子基因突变有相关性。
Objective To evaluate the correlation between CT and clinical features of lung adenocarcinoma and the exon 19 mutation of epidermal growth factor receptor (EGFR). Methods 581 patients underwent CT scan and EGFR gene detection, the need for qualitative assessment of CT and clinical features a total of 25. One-way comparative analysis and logistic regression model were used to analyze the correlation between EGFR wild type and exon 19 mutation. P value <0.05 for the difference was statistically significant. Results Of the 581 patients, 132 (22.7%) were mutant and 449 (77.3%) were wild-type. EFGR19 exon mutation was associated with the four features of smaller tumor diameter (OR = 0.982), female (OR = 0.380), pleural traction (OR = 2.093) and no fibrosis (OR = 0.288). Conclusion Some CT and clinical features of lung adenocarcinoma correlate with EGFR exon 19 mutations.